Literature DB >> 10943709

N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis.

O A Andreassen1, A Dedeoglu, P Klivenyi, M F Beal, A I Bush.   

Abstract

Increasing evidence implicates oxidative damage as a major mechanism in the pathogenesis of amyotrophic lateral sclerosis (ALS). We examined the effect of preventative treatment with N-acetyl-L-cysteine (NAC), an agent that reduces free radical damage, in transgenic mice with a superoxide dismutase (SODI) mutation (G93A), used as an animal model of familial ALS. NAC was administered at 1% concentration in the drinking water from 4-5 weeks of age. The treatment caused a significantly prolonged survival and delayed onset of motor impairment in G93A mice treated with NAC compared to control mice. These results provide further evidence for the involvement of free radical damage in the G93A mice, and support the possibility that NAC, an over-the-counter antioxidant, could be explored in clinical trials for ALS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10943709     DOI: 10.1097/00001756-200008030-00029

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  32 in total

1.  Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid β-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's disease.

Authors:  Renã A S Robinson; Gururaj Joshi; Quanzhen Huang; Rukhsana Sultana; Austin S Baker; Jian Cai; William Pierce; Daret K St Clair; William R Markesbery; D Allan Butterfield
Journal:  Proteomics       Date:  2011-09-22       Impact factor: 3.984

2.  Identification of early disease progression in an ALS rat model.

Authors:  Jason R Thonhoff; Paivi M Jordan; Joseph R Karam; Brandon L Bassett; Ping Wu
Journal:  Neurosci Lett       Date:  2007-01-14       Impact factor: 3.046

Review 3.  Posttranslational modifications in Cu,Zn-superoxide dismutase and mutations associated with amyotrophic lateral sclerosis.

Authors:  Yoshiaki Furukawa; Thomas V O'Halloran
Journal:  Antioxid Redox Signal       Date:  2006 May-Jun       Impact factor: 8.401

Review 4.  Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment.

Authors:  B Halliwell
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 5.  Neurodegenerative diseases: model organisms, pathology and autophagy.

Authors:  S N Suresh; Vijaya Verma; Shruthi Sateesh; James P Clement; Ravi Manjithaya
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

Review 6.  Amyotrophic lateral sclerosis: progress and prospects for treatment.

Authors:  Michel Dib
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Hypoxia-inducible factor 1 contributes to N-acetylcysteine's protection in stroke.

Authors:  Ziyan Zhang; Jingqi Yan; Saeid Taheri; Ke Jian Liu; Honglian Shi
Journal:  Free Radic Biol Med       Date:  2013-12-01       Impact factor: 7.376

Review 8.  Nutrition and dietary supplements in motor neuron disease.

Authors:  Jeffrey Rosenfeld; Amy Ellis
Journal:  Phys Med Rehabil Clin N Am       Date:  2008-08       Impact factor: 1.784

Review 9.  Therapeutic neuroprotective agents for amyotrophic lateral sclerosis.

Authors:  Rachna S Pandya; Haining Zhu; Wei Li; Robert Bowser; Robert M Friedlander; Xin Wang
Journal:  Cell Mol Life Sci       Date:  2013-07-18       Impact factor: 9.261

10.  Current and emerging treatments for amyotrophic lateral sclerosis.

Authors:  Stefano Zoccolella; Andrea Santamato; Paolo Lamberti
Journal:  Neuropsychiatr Dis Treat       Date:  2009-11-16       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.